1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy
    Meeting Abstract

    Till, J. E.; Abdalla, A.; Bhagwat, N.; Black, T. A.; Wang, Z. Y.; Yee, S. S.; Gherardini, P. F.; Kitch, L. J.; Selinsky, C.; Lyman, J. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer
    Meeting Abstract

    Tsimberidou, A. M.; Drakaki, A.; Khalil, D.; Kummar, S.; Hodi, F. S.; Oh, D. Y.; Cabanski, C. R.; Tezlaff, M.; LaVallee, T.; Spasic, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients
    Meeting Abstract

    Lacouture, M. E.; Anadkat, M. J.; Marathe, O. S.; Vogelzang, N. J.; Lam, E. T.; Kaffenberger, B.; Choi, J. N.; Webb, M. L.; Tyler, R. C.; Ju, J. G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)
    Meeting Abstract

    Grimes, J.; Shoushtari, A. N.; Orloff, M.; Khan, S.; Chiuzan, C.; Hsiao, S. J.; McDonnell, D.; Marr, B. P.; Carvajal, R. D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT)
    Meeting Abstract

    Riedell, P. A.; Hamadani, M.; Ahn, K. W.; Litovich, C.; Kharfan-Dabaja, M.; Herrera, A. F.; Sauter, C. S.; Smith, S. M.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC)
    Meeting Abstract

    Lee, E. K.; Xiong, N.; Tayob, N.; Krasner, C. N.; Buss, M. K.; Campos, S. M.; Wright, A. A.; Liu, J. F.; Shea, M.; Yeku, O. O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy
    Meeting Abstract

    Kurian, A. W.; Abrahamse, P.; Hamilton, A. S.; Deapen, D.; Gomez, S. L.; Morrow, M.; Berek, J. S.; Katz, S. J.; Ward, K. C.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of the PI3K delta inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24)
    Meeting Abstract

    Pagel, J. M.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Soumerai, J. D.; Llorin-Sangalang, J.; Gorbatchevsky, I.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2(+) breast leptomeningeal disease
    Meeting Abstract

    Ahmed, K. A.; Kim, Y.; DeJesus, M.; Kumthekar, P.; Williams, N. O.; Palmer, J. D.; Giglio, P.; Boire, A. A.; Arrington, J.; Sahebjam, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma
    Meeting Abstract

    Forrest, S. J.; Kinnaman, M. D.; Livingston, J. A.; Vo, K. T.; Merriam, P.; Clinton, C.; Desmith, K.; Cavanaugh, K.; Felicetti, B.; Smith, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save